OBJECTIVES:  This study aims to assess the level of competition between infliximab biosimilars (BIOSIM-INFLIX) and their originator (Remicade/infliximab, J&J/Merck) (ORIGIN-INFLIX) by analyzing the key global infliximab markets and the drivers of the BIOSIM-INFLIX uptakes. METHODS:  Data on medicine volumes, values and ex-manufacturing prices for BIOSIM-INFLIX and ORIGIN-INFLIX in the EU, in South Korea and in Japan were provided by IMS Health. Volumes were calculated in DDD (Defined Daily Doses) and Weighted Average Price (WAP) in euros/DDD. RESULTS:  In 2015, the highest BIOSIM-INFLIX uptake was found in Norway (67.8%) and the lowest was reported in Japan (1.1%). In EU countries where BIOSIM-INFLIX were marketed in 2015, their uptakes are still low (e.g. France, the UK, Germany, Italy and Spain with respectively 4.1%, 9.0%, 9.2%, 10.7% and 12.8% uptakes). In countries where BIOSIM-INFLIX are marketed since 2013, their uptakes are higher (e.g. Portugal, Czech Republic and Finland with respectively 15.1%, 20.6% and 32.5% uptakes). All countries have dominant hospital distributions for infliximab except Germany, Japan and Czech Republic which have mixed retail/hospital distributions. Germany is the country where BIOSIM-INFLIX is the most expensive (WAP = 21.7€/DDD) and Norway the country where it is the cheapest (WAP = 4.4€/DDD with a discount of 68.8% versus ORIGIN-INFLIX). But the relative price of BIOSIM-INFLIX versus ORIGIN-INFLIX does not always seem correlated to BIOSIM-INFLIX uptakes (e.g. in South Korea, the biosimilar uptake is 26.0%, whereas the WAP difference between BIOSIM-INFLIX and ORIGIN-INFLIX is of -5.2%; in Japan (BIOSIM-INFLIX uptake of 1.1%) this difference amounts to -33.2%). CONCLUSIONS:  Infliximab markets have proven to be highly country-specific. Today, the competition between BIOSIM-INFLIX and ORIGIN-INFLIXseems not mainly based on prices, but on local decision-making and purchasing process. Due to the limited experience on the use of BIOSIM-INFLIX our results have to be confirmed in the future.